Skip to main content
. 2017 Jun 15;108(6):1223–1230. doi: 10.1111/cas.13241

Figure 4.

Figure 4

Maximum change in target‐lesion diameter in relation to BRAF genotype in Japanese patients with previously untreated advanced melanoma given nivolumab (n = 23). Maximum changes in target‐lesion diameter from baseline evaluated by independent radiology review committee. Purple and yellow bars represent patients with BRAF wild‐type and mutation, respectively.